We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
Read MoreHide Full Article
Key Takeaways
Sarepta shares rose after progress on its phase I/II SRP-1003 study for DM1.
The company advanced dosing after a positive safety committee review of the program.
The update also triggered a $200M milestone payment to Arrowhead under its licensing deal.
Shares of Sarepta Therapeutics (SRPT - Free Report) rose 7% on Monday after the company announced its progress on a phase I/II study evaluating SRP-1003, an investigational small interfering RNA (siRNA) therapeutic for type 1 myotonic dystrophy (DM1).
While Sarepta has completed two cohorts of this study, it has completed enrolling patients in a third cohort. The company also announced a positive review from a pre-specified drug safety committee for this study, based on which it has decided to advance additional drug escalating cohorts. While Sarepta is currently dosing patients in a fourth cohort, it plans to start dosing patients in the final fifth cohort in the first quarter of 2026.
Initial readout from this study is also expected early next year.
SRPT’s Stock Performance
Post the above announcement, investors cheered the news. One Wall Street analyst viewed this update as positive, considering the safety issues experienced with investigational DM1 therapies being developed by companies like Avidity Biosciences (RNA - Free Report) and PepGen (PEPG - Free Report) .
Some investors also expressed optimism around the stock, which has been facing heat from investors since the start of this year due to a slew of negative updates centered around Sarepta’s Duchenne muscular dystrophy (DMD) therapies.
Year to date, the stock has plummeted nearly 85% against the industry’s 17% growth.
Image Source: Zacks Investment Research
Sarepta’s DM1 Update Triggers Milestone Payment
The above event triggered a milestone payment of $200 million to partner Arrowhead Pharmaceuticals . SRP-1003 was acquired by Sarepta earlier this year as part of a multi-billion-dollar licensing deal with Arrowhead.
This marks the second milestone payment triggered this year. In July, Arrowhead earned the first milestone payment of $100 million when it reached the first of two prespecified enrollment targets and received regulatory approval to start dose escalation in the above study. To fund this payment, Sarepta announced the sale of its equity stake worth $174 million in Arrowhead in August.
Apart from SRP-1003, Sarepta also acquired exclusive rights to Arrowhead’s three more clinical-stage programs, each being evaluated in separate phase I/II studies. These include SRP-1001 in facioscapulohumeral muscular dystrophy (FSHD), SRP-1002 in idiopathic pulmonary fibrosis (IPF) and SRP-1004 in spinocerebellar ataxia 2 (SCA2). Initial data on the FSHD program is expected in early 2026.
Image: Bigstock
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
Key Takeaways
Shares of Sarepta Therapeutics (SRPT - Free Report) rose 7% on Monday after the company announced its progress on a phase I/II study evaluating SRP-1003, an investigational small interfering RNA (siRNA) therapeutic for type 1 myotonic dystrophy (DM1).
While Sarepta has completed two cohorts of this study, it has completed enrolling patients in a third cohort. The company also announced a positive review from a pre-specified drug safety committee for this study, based on which it has decided to advance additional drug escalating cohorts. While Sarepta is currently dosing patients in a fourth cohort, it plans to start dosing patients in the final fifth cohort in the first quarter of 2026.
Initial readout from this study is also expected early next year.
SRPT’s Stock Performance
Post the above announcement, investors cheered the news. One Wall Street analyst viewed this update as positive, considering the safety issues experienced with investigational DM1 therapies being developed by companies like Avidity Biosciences (RNA - Free Report) and PepGen (PEPG - Free Report) .
Some investors also expressed optimism around the stock, which has been facing heat from investors since the start of this year due to a slew of negative updates centered around Sarepta’s Duchenne muscular dystrophy (DMD) therapies.
Year to date, the stock has plummeted nearly 85% against the industry’s 17% growth.
Image Source: Zacks Investment Research
Sarepta’s DM1 Update Triggers Milestone Payment
The above event triggered a milestone payment of $200 million to partner Arrowhead Pharmaceuticals . SRP-1003 was acquired by Sarepta earlier this year as part of a multi-billion-dollar licensing deal with Arrowhead.
This marks the second milestone payment triggered this year. In July, Arrowhead earned the first milestone payment of $100 million when it reached the first of two prespecified enrollment targets and received regulatory approval to start dose escalation in the above study. To fund this payment, Sarepta announced the sale of its equity stake worth $174 million in Arrowhead in August.
Apart from SRP-1003, Sarepta also acquired exclusive rights to Arrowhead’s three more clinical-stage programs, each being evaluated in separate phase I/II studies. These include SRP-1001 in facioscapulohumeral muscular dystrophy (FSHD), SRP-1002 in idiopathic pulmonary fibrosis (IPF) and SRP-1004 in spinocerebellar ataxia 2 (SCA2). Initial data on the FSHD program is expected in early 2026.
Sarepta Therapeutics, Inc. Price
Sarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote
SRPT’s Zacks Rank
Sarepta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.